Skip to main content

Ross Camidge MD, PhD

Dr Ross Camidge is the Director of the Thoracic Oncology Clinical Program at the University of Colorado in Aurora, USA. 

His focus is in thoracic malignancies and developmental therapeutics, and is dual-trained in both medical oncology and clinical pharmacology.

He is the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) and a member of the National Comprehensive Cancer Network Lung Cancer Committee.

As well as being a principal investigator on numerous clinical trials in early phase drug development and thoracic malignancies, he has authored more than 150 articles in peer-reviewed journals and presented his research at multiple national and international scientific meetings.


Latest contributions from Ross Camidge

ALK-ROS Panel discussion teaser

28-03-2022 | Non-small-cell lung cancer | Video

ALK fusion-positive NSCLC: International approaches to management

Ross Camidge leads Rosario García Campelo and Yongchang Zhang in a discussion on the detection and treatment of ALK fusion-positive NSCLC in current practice.

Ross Camidge

02-10-2019 | Non-small-cell lung cancer | Video | Article

Expert highlights: Lung and thoracic cancers at ESMO 2019

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

Ross Camidge Expert Highlights

08-09-2019 | Lung cancer | Video | Article

Expert highlights from WCLC 2019

WATCH | Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

Relay race

11-06-2019 | Non-small-cell lung cancer | Conference coverage | News

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.